Paul D. Robbins

Robbins presents a concrete and scientifically grounded strategy for extending healthspan through senotherapeutics targeting multiple hallmarks of aging. His influential, sustained research program supports the durability of this direction, but the evidence contains no explicit destination vision, human-lifespan objective, development timeline, or discussion of translational risks.

Robbins demonstrates field-defining scientific influence, particularly in cellular senescence and senolytics. His exceptional citation profile is reinforced by several foundational geroscience papers with more than 1,000 citations each, showing influence well beyond publication volume.

The evidence establishes Robbins's substantial scientific impact but identifies no investments, donations, or other deployment of personal or controlled capital. Scientific achievements alone do not make the capital_deployed dimension applicable.

No public capital deployment activity is evidenced for this scientist.

Robbins’s publication record shows a coherent translational bet on cellular senescence: defining the mechanism, identifying senolytic compounds, and demonstrating healthspan and lifespan effects. The highly cited 2015–2018 work suggests that this research direction helped establish senotherapeutics as a consequential longevity pathway. However, the evidence does not establish his individual decision-making role, the contemporaneous contrarian nature of the bet, or a clear counterfactual showing that the path depended on him.

Field creation is applicable, but the supplied evidence establishes scientific collaboration and protocol-relevant research rather than creation of organizations, programs, categories, communities, protocols, or funding paths. Robbins is affiliated with an aging institute, but no evidence shows that he founded it or created a field-building structure.

The dimension applies, but the supplied evidence documents scientific productivity and mainstream institutional research rather than public risk-taking or conviction. No qualifying bravery exhibit, career sacrifice, contrarian stance, persistence under serious criticism, consequential personal bet, or self-experimentation is shown.

Robbins demonstrates substantial second-order scientific leverage: his highly cited senescence and senolytic research has influenced a large body of follow-on work, while extensive multi-institutional collaborations and participation in a regional geroscience consortium indicate field-building reach beyond his laboratory. Evidence for attracting capital, founding organizations, shaping policy, or generating companies is absent, limiting a higher score.